|Bid||9.49 x 1400|
|Ask||11.50 x 1200|
|Day's Range||9.87 - 10.20|
|52 Week Range||5.42 - 15.08|
|Beta (3Y Monthly)||2.21|
|PE Ratio (TTM)||40.89|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.75|
-- Studies highlight CCX4503, a unique small molecule inhibitor of immune checkpoint molecules PD-1/PD-L1, demonstrates anti-tumor efficacy in vivo ---- Company’s studies also.
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
MOUNTAIN VIEW, Calif., Nov. 20, 2018 -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at.
ChemoCentryx (CCXI) delivered earnings and revenue surprises of 12.00% and -22.29%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Mountain View, California-based company said it had a loss of 22 cents per share. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
-- Large, controlled clinical trial of avacopan in Hidradenitis Suppurativa (HS) on track to launch in late 2018 – -- $186 million in cash and investments at September 30, 2018.
MOUNTAIN VIEW, Calif., Nov. 01, 2018 -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's third quarter 2018 financial results will be released after.
ChemoCentryx (CCXI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ChemoCentryx, Inc., (CCXI), today announced presentations of its lead drug candidates avacopan, a complement 5a receptor inhibitor, and CCX140, an inhibitor of the chemokine receptor known as CCR2, during the American Society of Nephrology (ASN) Kidney Week 2018, the world's premier nephrology meeting, being held October 23-28 in San Diego. In an informational poster session on October 25 from 10:00 a.m. to 12:00 p.m. PT, researchers will highlight the ongoing ADVOCATE Phase III pivotal trial of avacopan, ChemoCentryx’s novel, orally bioavailable, highly selective antagonist of human C5a receptor, in patients with active anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV).
NEW YORK, Oct. 16, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
ChemoCentryx, Inc. (the "Company" or "ChemoCentryx") (CCXI) announced today that it will not conclude an offering of shares of its common stock as announced on Wednesday, September 26, 2018. The offering was being made pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission on April 28, 2016.
Comparable sales were down 0.6 percent, while analysts expected a 0.3 percent increase. Kimbell Royalty Partners KRP stock dipped almost 6 percent in the extended session after the company announced a public offering of 3 million shares of common stock. ChemoCentryx CCXI shares fell as much as 12 percent in after-hours trading following an announcement that the biopharmaceutical company has commenced a public offering of $75 million worth of common stock.
MOUNTAIN VIEW, Calif., Sept. 26, 2018-- ChemoCentryx, Inc.,, today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the Cantor Fitzgerald 2018 Global Healthcare ...
Vifor Pharma Group acquires an additional 7,343,492 common shares of ChemoCentryx, Inc. (CCXI) from GlaxoSmithKline - an additional 14.6% stake in the company. As a result Vifor Pharma Group will hold a total of 21.2% of ChemoCentryx on completion of the transaction. The increased investment follows the establishment of a partnership with ChemoCentryx, which began in May 2016.
ChemoCentryx (CCXI) delivered earnings and revenue surprises of -27.27% and -11.02%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Mountain View, California-based company said it had a loss of 14 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
Johnson & Johnson (JNJ) has been ordered to pay $4.69 billion in damages to 22 families who alleged that the company's baby powder contained asbestos that caused them to develop ovarian cancer.
Bristol-Myers' (BMY) Opdivo in combination with its Yervoy received the FDA approval to treat patients with metastatic colorectal cancer (mCRC) that has progressed following treatment with fluoropyrimidine, oxaliplatin and irinotecan.